Literature DB >> 24357839

Local safety of repeated intravitreal Ozurdex.

P Hernández-Martínez1, R Gallego-Pinazo1, S Martínez-Castillo1, R Dolz-Marco1, M Díaz-Llopis2.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24357839      PMCID： PMC3965809          DOI： 10.1038/eye.2013.265

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  3 in total

1.  Anterior chamber migration of dexametasone intravitreal implant (Ozurdex®).

Authors:  Diamar Pardo-López; Ester Francés-Muñoz; Roberto Gallego-Pinazo; Manuel Díaz-Llopis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-23       Impact factor: 3.117

2.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup
Journal:  Ophthalmology       Date:  2010-04-24       Impact factor: 12.079

3.  Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion.

Authors:  W J Mayer; A Wolf; M Kernt; D Kook; A Kampik; M Ulbig; C Haritoglou
Journal:  Eye (Lond)       Date:  2013-04-19       Impact factor: 3.775
  3 in total
  2 in total

1.  Response to Hernández-Martínez et al.

Authors:  W J Mayer; A Wolf; M Kernt; D Kook; A Kampik; M Ulbig; C Haritoglou
Journal:  Eye (Lond)       Date:  2013-12-20       Impact factor: 3.775

2.  Intravitreal steroids for macular edema in diabetes.

Authors:  Thanitsara Rittiphairoj; Tahreem A Mir; Tianjing Li; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2020-11-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.